Laboratory of Molecular Immunology, Department of Animal Resource Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Front Immunol. 2023 Mar 9;14:1110583. doi: 10.3389/fimmu.2023.1110583. eCollection 2023.
In today's aging society, dementia is an urgent problem to be solved because no treatment or preventive methods have been established. This review focuses on oral administration of lipopolysaccharide (LPS), an outer membrane component of Gram-negative bacteria, as a novel preventive drug for dementia. LPS is also called endotoxin and is well known to induce inflammation when administered systemically. On the other hand, although we humans routinely ingest LPS derived from symbiotic bacteria of edible plants, the effect of oral administration of LPS has hardly been studied. Recently, oral administration of LPS was reported to prevent dementia by inducing neuroprotective microglia. Furthermore, it has been suggested that colony stimulating factor 1 (CSF1) is involved in the dementia prevention mechanism by oral administration of LPS. Thus, in this review, we summarized the previous studies of oral administration of LPS and discussed the predicted dementia prevention mechanism. In addition, we showed the potential of oral LPS administration as a preventive drug for dementia by highlighting research gaps and future issues for clinical application development.
在当今老龄化社会,痴呆症是一个亟待解决的问题,因为目前还没有确立治疗或预防方法。本综述重点介绍了革兰氏阴性菌外膜成分脂多糖(LPS)作为一种新型痴呆症预防药物的口服给药。LPS 也称为内毒素,当全身给药时,它会引起炎症,这是众所周知的。另一方面,尽管我们人类经常摄入来源于可食用植物共生菌的 LPS,但对 LPS 的口服给药的效果几乎没有研究。最近,有报道称口服 LPS 通过诱导神经保护性小胶质细胞来预防痴呆症。此外,据报道,口服 LPS 通过集落刺激因子 1(CSF1)参与痴呆症的预防机制。因此,在本综述中,我们总结了 LPS 口服给药的先前研究,并讨论了预测的痴呆症预防机制。此外,我们通过突出研究空白和未来的临床应用发展问题,展示了口服 LPS 给药作为预防痴呆症药物的潜力。